金河生物(002688.SZ):放棄控股子公司金河製藥部分少數股東股權優先受讓權及向其增資
格隆匯3月12日丨金河生物(002688.SZ)公佈,控股子公司內蒙古金河製藥科技有限公司(簡稱“金河製藥”或“標的公司”)少數股東路牡丹、李福忠等11人擬將其所持有的金河製藥全部股份和張鴻毅所持有的金河製藥部分股份合計930萬元(佔比18.60%)轉讓於自然人方軍、徐兵、郭奇龍。公司同意放棄在同等條件下就金河製藥部分股權轉讓所享有的優先受讓權。
爲進一步擴大金河製藥資本實力、支持其業務發展,金河生物、徐兵擬對完成少數股東股權轉讓後的金河製藥共同增資,合計增資金額4,000萬元。其中,金河生物向其增資3,525萬元(以債轉股方式增資2,700萬元,以自有資金貨幣現金方式增資825萬元),徐兵以自籌資金貨幣現金方式向其增資475萬元。增資完成後金河生物持有金河製藥股權比例由51%增加至67.50%,金河製藥仍是金河生物控股子公司,不影響公司的合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.